Abstract | OBJECTIVE AND DESIGN: MATERIAL OR SUBJECTS: BALB/c and C57BL/6 mice were used as donors and recipients, respectively. TREATMENT: C57BL/6 mice were given 2 Gy total-body irradiation, followed by an intravenous injection of 2 × 10(7) BALB/c bone marrow cells (BMCs). Mice were treated with LEF daily at a dose of 30 mg/kg/day for 2 weeks. RESULTS: In naïve mice, LEF significantly decreased the percentage of CD4(+)CD25(+) Treg cells in spleens (P < 0.05), but not in lymph nodes, though LEF enhanced the percentages of CD4(+)CD25(+) Treg cells in CD4 single positive cells in the thymocytes and blood (P < 0.05). Furthermore, LEF significantly decreased the percentage of CD4(+)CD25(+) Treg cells in the spleens of mice that received allogeneic BMCs. CONCLUSIONS: LEF decreases peripheral CD4(+)CD25(+) Treg cells in un-immunizing and immunizing recipients, indicating that LEF might not be an ideal candidate for the treatment of autoimmune diseases or graft rejection with respect to induction of immune tolerance.
|
Authors | Di Jin, Kaizhong Duan, Lianjun Zhang, Jianxia Peng, Yong Zhao |
Journal | Inflammation research : official journal of the European Histamine Research Society ... [et al.]
(Inflamm Res)
Vol. 61
Issue 1
Pg. 53-60
(Jan 2012)
ISSN: 1420-908X [Electronic] Switzerland |
PMID | 22057872
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Forkhead Transcription Factors
- Foxp3 protein, mouse
- Interleukin-2 Receptor alpha Subunit
- Isoxazoles
- Leflunomide
|
Topics |
- Animals
- Antibodies, Monoclonal
(chemistry)
- Autoimmune Diseases
(metabolism)
- Bone Marrow Transplantation
(methods)
- CD4-Positive T-Lymphocytes
(cytology)
- Female
- Forkhead Transcription Factors
(biosynthesis)
- Interleukin-2 Receptor alpha Subunit
(biosynthesis)
- Isoxazoles
(pharmacology)
- Leflunomide
- Leukocytes, Mononuclear
(cytology)
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- T-Lymphocytes, Regulatory
(cytology)
|